EWM
VNDA icon

Edge Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Edge Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,500
Closed -$38K – 373
2013
Q3 		$38K Buy
3,500
+1,500
+75% +$16K 0.02% 161
2013
Q2 		$16K Buy
+2,000
New +$13.5K 0.01% 199

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Edge Wealth Management's VNDA Position: Q4 2013 in Review

Edge Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2013, closing a stake of 3,500 shares — an estimated $38K sold.

Edge Wealth Management first reported a position in VNDA in Q2 2013 and held it in 2 quarters. The position peaked at $38K in Q3 2013. 86 funds tracked by Wall St. Rank hold VNDA as of Q4 2013.

  • Edge Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Edge Wealth Management sold 3,500 Vanda Pharmaceuticals shares in Q4 2013, an estimated $38K.
  • Edge Wealth Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Edge Wealth Management's Vanda Pharmaceuticals position peaked at $38K in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2013.

Based on Edge Wealth Management's 13F filing for Q4 2013, filed 16 Jan 2014.